- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
Détention brevets de la classe A61K 40/15
Brevets de cette classe: 284
Historique des publications depuis 10 ans
|
0
|
0
|
0
|
3
|
5
|
8
|
12
|
6
|
5
|
138
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Immunitybio, Inc. | 417 |
15 |
| Board of Regents, The University of Texas System | 5891 |
11 |
| Takeda Pharmaceutical Company Limited | 2704 |
8 |
| Nkarta, Inc. | 66 |
8 |
| FATE Therapeutics, Inc. | 209 |
7 |
| GC Cell Corporation | 53 |
7 |
| University of Central Florida Research Foundation, Inc. | 1206 |
6 |
| Research Institute at Nationwide Children's Hospital | 570 |
5 |
| The Regents of the University of California | 20153 |
4 |
| Memorial Sloan-Kettering Cancer Center | 1963 |
4 |
| Sloan-Kettering Institute for Cancer Research | 533 |
4 |
| Indapta Therapeutics Inc. | 20 |
4 |
| Memorial Hospital for Cancer and Allied Diseases | 310 |
4 |
| Shoreline Biosciences, Inc. | 14 |
4 |
| The Johns Hopkins University | 5730 |
3 |
| City of Hope | 1002 |
3 |
| Dana-Farber Cancer Institute, Inc. | 2602 |
3 |
| National University of Singapore | 2488 |
3 |
| Oslo Universitetssykehus HF | 190 |
3 |
| Celularity, Inc. | 187 |
3 |
| Autres propriétaires | 175 |